Logo

Y-mAbs Reports the Submission of Naxitamab's BLA to the US FDA for Relapsed/Refractory High-Risk Neuroblastoma

Share this
Y-mAbs Reports the Submission of Naxitamab's BLA to the US FDA for Relapsed/Refractory High-Risk Neuroblastoma

Y-mAbs Reports the Submission of Naxitamab's BLA to the US FDA for Relapsed/Refractory High-Risk Neuroblastoma

Shots:

  • Y-mAbs has submitted the BLA the US FDA under the FDA’s Rolling Review process for naxitamab following the market closure on Mar 31- 2020
  • The BLA submission is based on two P-II studies- 201 and 12-230 assessing the safety & efficacy of the therapy- which the company expects to present at a venue later this year
  • Naxitamab is an investigational mAb- targeting GD2 having the potential to address the unmet medical needs of patients with relapsed/refractory high-risk neuroblastoma. The therapy was initially developed by MSK and exclusively licensed to Y-mAbs

Click here to­ read full press release/ article | Ref: Y-mAbs | Image: Y-mAbs


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions